Field, M.; Splevins, A.; Picaut, P.; Van der Schans, M.; Langenberg, J.; Noort, D.; Foster, K.
AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins 2018, 10, 535.
https://doi.org/10.3390/toxins10120535
AMA Style
Field M, Splevins A, Picaut P, Van der Schans M, Langenberg J, Noort D, Foster K.
AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018; 10(12):535.
https://doi.org/10.3390/toxins10120535
Chicago/Turabian Style
Field, Malgorzata, Andrew Splevins, Philippe Picaut, Marcel Van der Schans, Jan Langenberg, Daan Noort, and Keith Foster.
2018. "AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients" Toxins 10, no. 12: 535.
https://doi.org/10.3390/toxins10120535
APA Style
Field, M., Splevins, A., Picaut, P., Van der Schans, M., Langenberg, J., Noort, D., & Foster, K.
(2018). AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins, 10(12), 535.
https://doi.org/10.3390/toxins10120535